Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492636 | 0.91 | LTB4R (0.41) | ADORA3ADORA1CDC7LTB4RKDM4E | |
| SCHEMBL5555331 | 0.91 | PDE4A (0.40) | ADORA3ADORA1CDC7LTB4RKDM4E | |
| SCHEMBL18102016 | 0.90 | ADORA3 (0.40) | ADORA3ADORA1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20841754 | 0.90 | CTSV (0.37) | ADORA3ADORA1CDC7LTB4RKDM4E | |
| SCHEMBL20543647 | 0.88 | ADORA3 (0.34) | ADORA3ADORA1CDC7LTB4RKDM4E | |
| SCHEMBL19206667 | 0.88 | LTB4R (0.39) | ADORA3CDC7LTB4RKDM4EALDH1A1 | |
| SCHEMBL17407642 | 0.87 | ALKBH3 (0.38) | CDC7LTB4RKDM4EALDH1A1HSD17B10 | |
| SCHEMBL20543762 | 0.87 | ADORA3 (0.34) | ADORA3ADORA1CDC7LTB4RKDM4E | |
| SCHEMBL19206747 | 0.87 | DHFR (0.37) | ADORA3ADORA1CDC7KDM4EALDH1A1 | |
| SCHEMBL20841748 | 0.86 | ALKBH3 (0.41) | ADORA3CDC7LTB4RKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| CN-106148362-B | Novel coelenterazine substrates and methods of use thereof | 普罗梅加公司 | 2021-04-30 | — | — | CN | disclosed |
| EP-2635595-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | RNGTT, UPF1, NSUN2 | ADORA3 3755/4885ADORA1 4009/4885CDC7 1456/4885 |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ADORA3 3764/4885ADORA1 4148/4885CDC7 1373/4885 |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | ADORA3 3764/4885ADORA1 4148/4885CDC7 1373/4885 |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | ADORA3 3764/4885ADORA1 4148/4885CDC7 1373/4885 |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ADORA3 3764/4885ADORA1 4148/4885CDC7 1373/4885 |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ADORA3 3764/4885ADORA1 4148/4885CDC7 1373/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | ADORA3 4205/4885ADORA1 4671/4885CDC7 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.